Proposals are invited for organizing Symposia/Workshops at OMICS Group Conferences or OMICS Group will sponsor small events at your universities in related areas under the title of your own. These proposals can be sent to respective conference mail ids or to symposia@omicsonline.org.
Day 1  September 24, 2014

08:30-09:00  Registrations

Auditorium 3A

09:00-09:30  Opening Ceremony

Keynote Forum

09:30-09:35  Introduction
Ray Spier
University of Surrey, UK

09:35-10:00  Ray Spier
University of Surrey, UK

10:00-10:25  Michael G Hanna
Vaccinogen, Inc., USA

10:25-10:50  Nikolai Petrovsky
Flinders Medical Centre Research, Australia

Vaccine adjuvants
Session Chair: Nikolai Petrovsky, Flinders Medical Centre Research, Australia

11:15-11:35  Inter-bilayer cross-linked multi-lamellar vesicles (ICMVs) for efficient co-delivery of antigen and adjuvant payloads
Alan R Shaw, Vedanta Pharmaceuticals, USA

11:35-11:55  Adjuvant-guidance of T cell responses
Magdalena Tary-Lehmann, Cellular Technology Limited, USA

11:55-12:15  Antibody targeting of human T cell CD27 identifies genes and pathways related to inflammation
Venky Ramakrishna, CellDex Therapeutics, USA

12:15-12:35  Evaluation of ZOSTAVAX® via the intradermal route using the MicronJet™
Brian K. Meyer, Merck & Co., USA

12:35-12:55  Universal influenza vaccines: Prevention of infection against matched and mismatched strains
Harry Kleanthous, Sanofi-Pasteur, Inc., USA

12:55-13:15  DNA vaccines which encode natural adjuvants are more effective than canonical DNA vaccines
Eric James Gowans, The University of Adelaide, South Australia

Lunch Break 13:15-14:00 @ Multi Purpose Hall 2

14:00-14:20  Immune memory resilience, a new way of evaluating adjuvants
Jean-Pierre Y Scheerlinck, The University of Melbourne, Australia

14:20-14:40  Novel lipid based adjuvants and delivery systems for induction of CD8 T cell immunity
Lakshmi Krishnan, National Research Council-Human Health Therapeutics, Canada

14:40-15:00  Establishment of lipid-based immunogens for the development of novel subunit vaccines
Chih-Hsiang Leng, National Health Research Institutes, Taiwan

15:00-15:20  Highly immunogenic C-terminal binding domain of Clostridium difficile toxin a stimulates dendritic cell maturation
Pele Choi-Sing Chong, National Health Research Institutes, Taiwan

Coffee Break 15:20-15:35 @ Auditorium 3 Foyer

15:35-15:55  The Cronobacter sakazakii ESP2949-1 phage induces dendritic cell maturation via activation of nuclear factor-kB and IL-12p40 in murine bone marrow
Hyo-Ilh Chang, Korea University, Korea

15:55-16:15  Nasal administration of antigens using maltodextrin nanoparticles: A mechanistic study
Didier Betbeder, University of Luille2, France

16:15-16:35  Stabilized liposomes carrying bee venom new formulation is the breakthrough of pain and anaphylaxis and death in mice under venom immunotherapy
Maria Helena Bueno da Costa, Scientific Consultant, France

16:35-16:55  Live vaccine for equine influenza on the base of cold-adapted recombinant strain A/HK0tar/6:2/2010
Sandybayev Nural, Research Institute for Biological Safety Problems, Republic of Kazakhstan

16:55-17:15  Polio outbreak in the Middle East: Update
Randa Hamadeh, Ministry of Public Health, Lebanon

17:15-17:35  Outer membrane vesicle of bacteria: Friend or Foe?
Seyed Davar Siadat, Pasteur Institute of Iran, Iran

17:35-17:55  Adjuvant properties of outer-membrane-vesicle in hepatitis B surface based vaccine
Arfa Moshiri, Shahid Beheshti University of Medical Sciences, Iran

Coffee Break 11:00-11:15 @ Auditorium 3 Foyer

Group Photo
17:55-18:15 Role of interferon gamma as immune adjuvant in Labeor ohita
Megha Kadam Bedekar, Central Institute of Fisheries Education, India

Panel Discussion 18:15-18:25
Breakout @ Committee Room 6-7

Biodefense vaccine

Session Chair: Leonard A Smith, United States Army Medical Research Institute of Infectious Diseases, USA

11:15-11:35 Finding a safe, efficacious and stable vaccine in the ricin protein fold
Leonard A Smith, United States Army Medical Research Institute of Infectious Diseases, USA
A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome delivered by intramuscular electroporation

11:35-11:55 A non-replicating, new generation smallpox vaccine available for updating
Connie S Schmaljohn, United States Army Medical Research Institute of Infectious Diseases, USA
MVA-BN® (IMVANEX®/IMVAMUNE®): smallpox preparedness plans

11:55-12:15 A vaccine pipeline: Using phage display for identification of immunogenic proteins and generation of human antibodies for diagnostics and therapy
Michael Hust, Technische Universität Braunschweig, Germany

12:15-12:35 Biodefense vaccine
Session Chair: Leonard A Smith, United States Army Medical Research Institute of Infectious Diseases, USA

11:15-11:35 Finding a safe, efficacious and stable vaccine in the ricin protein fold
Leonard A Smith, United States Army Medical Research Institute of Infectious Diseases, USA
A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome delivered by intramuscular electroporation

11:35-11:55 A non-replicating, new generation smallpox vaccine available for updating
Connie S Schmaljohn, United States Army Medical Research Institute of Infectious Diseases, USA
MVA-BN® (IMVANEX®/IMVAMUNE®): smallpox preparedness plans

11:55-12:15 A vaccine pipeline: Using phage display for identification of immunogenic proteins and generation of human antibodies for diagnostics and therapy
Michael Hust, Technische Universität Braunschweig, Germany

12:15-12:35 Veterinary vaccines
Session Chair: Jean L Patterson, Texas Biomedical Research Institute, USA

13:30-13:50 Quality and consistency of cell culture media with a highlight on FMDV
Serge Ohreser, Merck Millipore, France

13:50-14:10 Vaccine development at animal biosafety level four: Standards and challenges
Jean L Patterson, Texas Biomedical Research Institute, USA

14:10-14:30 Low dose antigen exposure in extreme early life promotes adaptive immune response in lambs and piglets
Heather L Wilson, University of Saskatchewan, Canada

14:30-14:50 Study immune correlates of vaccine-induced protective immunity against rotavirus infection and diarrhea using B cell deficient neonatal gnotobiotic pigs
Lijuan Yuan, Virginia Polytechnic Institute and State University, USA

14:50-15:10 Targeting aminopeptidase N on enterocytes rapidly induces an IgA response in a pig model
Eric Cox, Ghent University, Belgium

15:10-15:30 Low dose antigen exposure in extreme early life promotes adaptive immune response in lambs and piglets
Heather L Wilson, University of Saskatchewan, Canada

15:30-15:50 Study immune correlates of vaccine-induced protective immunity against rotavirus infection and diarrhea using B cell deficient neonatal gnotobiotic pigs
Lijuan Yuan, Virginia Polytechnic Institute and State University, USA

15:50-16:10 Targeting aminopeptidase N on enterocytes rapidly induces an IgA response in a pig model
Eric Cox, Ghent University, Belgium

16:05-16:25 Use of ORF-1 product Rep in prevention and diagnosis of porcine circovirosis
Silvia Pellicer, World Pathol, Spain

16:25-16:45 Coffee Break 15:30-15:45 @ Auditorium 3 Foyer

16:45-17:05 Use of viral interference against avian influenza and establishment of protection levels in field outbreaks in Mexico
Inkar Castellanos, Viren SA de CV, Mexico

17:05-17:15 Panel Discussion 17:05-17:15

Day 2 September 25, 2014
Auditorium 3A

Keynote Forum

09:00-09:05 Introduction
09:05-09:30 Geert Vanden Bossche
UNIVAC LLC., Belgium
09:30-09:55 Jeffrey Ulmer
Novartis Vaccines & Diagnostics, USA

Group Photo

Therapeutic vaccines for chronic infecti
Session Chair: Jeffrey Ulmer, Novartis Vaccines & Diagnostics, USA

10:05-10:25 Mimogen-a new strategy for post-exposure vaccine development
Yuzhang Wu, Third Military Medical University, China

10:25-10:45 Generation of robust immunity following DNA vaccine immunization enhanced by intradermal electroporation
Kate E Broderick, Inovio Pharmaceuticals, USA
10:45-11:05 M2SR, a robust flu vaccine with long-lasting, cross-protective immunity
Pamuk Bilsel, Flugen Inc., USA

Coffee Break 11:05-11:20 @ Auditorium 3 Foyer

11:20-11:40 In vivo electroporation for improvement of therapeutic DNA vaccine against chronic hepatitis B infection
Lucyna Cova, INSERM, France

11:40-12:00 A Synthetic multi-antigen approach targeting Plasmodium falciparum malaria
Bernadette Ferrari, University of Pennsylvania, USA

12:00-12:20 Pneumococcal infections and vaccination
Birgitta Henriques-Normark, Karolinska Institute, Sweden

12:20-12:40 Heat shock protein complex vaccines against mucosal pathogenic bacteria
Phil Sutton, Murdoch Childrens Research Institute, Australia

12:40-13:00 Upgrading the 100 year-old BCG vaccine
Zakaria Hmama, University of British Columbia, Canada

Lunch Break 13:00-13:45 @ Multi Purpose Hall 2

13:45-14:05 Immunization with neuraminidase deficient influenza virus is highly immunogenic and non-pathogenic to wild type and immunocompromised mice
Alexandre M. Vieira Machado - Fiocruz, Rene Rachou Research Center, Brazil

14:05-14:25 Design and evaluation of a novel OspA-based vaccine for the prevention of Lyme borreliosis
Andreas Meinke, Valneva Austria GmbH, Austria

14:25-14:45 Therapeutic vaccines for drug-resistant tuberculosis
Tijp van der Werf, University of Groningen, The Netherlands

14:45-15:05 Vaccination in risk groups with special focus on non-responsive to routine vaccines
Ursula Wiedermann, Medical University of Vienna, Austria

15:05-15:25 Post challenging effects of new formulation of leishmania major antigen in Balb/c mice
Latifynia Afshineh, Tehran University of Medical Sciences, Iran

Coffee Break 15:25-15:40 @ Auditorium 3 Foyer

15:40-16:00 Immunological studies on tetanus toxoid
Rakesh Kumar, Serum Institute of India Limited, India

16:00-16:20 Process development and immunogenicity studies on a serogroup ‘X’ meningococcal polysaccharide conjugate vaccine
Srinivas Reddy, Serum Institute of India Ltd., India

16:20-16:40 Self-adjuvanting promiscuous peptide of Mycobacterium tuberculosis augments polyfunctional Th17 cells and evokes better memory T cell response than BCG
Javed N Agrewala, CSIR - Institute of Microbial Technology, India

16:40-17:00 Immunogenicity and therapeutic effects of Ag85A/B chimeric DNA vaccine in mice infected with Mycobacterium tuberculosis
Xueqiong Wu, the 309th Hospital of Chinese PLA, China

17:00-17:20 Speciation of chromium in medicinal plants from selected farms in the vicinity of ferrochrome
Isiaka Alade Owolabi, Tshwane University of Technology, South Africa

Panel Discussion 17:20-17:30

16:30-17:30 Special Session for Students: Nikolai Petrovsky @ Community Hall 1-2
Scientific writing, Journal review, Grant writing, Strategies for building a scientific career and Scientific careers outside of research
Breakout @ Committee Room 6-7

Cancer vaccines
Session Chair: Michael G Hanna, Vaccinogen, Inc., USA

10:05-10:25 From viruses to tumor associated antigen cancer vaccines
Giulio Tarro, Temple University Center for Biotechnology, USA

10:25-10:45 Measles Virus vaccine infects tumor cells and induces dendritic cells (DC) maturation and tumor antigen cross-presentation
Marc GREGOIRE, Institut de Recherche en Sante Universite de Nantes, INSERM, France

10:45-11:05 Personalized therapeutic cancer vaccine development to treat metastatic diseases
Periasamy Selvaraj, Emory University, USA

Coffee Break 11:05-11:20 @ Auditorium 3 Foyer

11:20-11:40 Teaching self-destructing Salmonella new tricks to fight cancer
Wei Kong, Arizona State University, USA

11:40-12:00 DC targeting skin vaccines for improved cancer immunotherapy
Yvette van Kooyk, VU University Medical Center, The Netherlands

12:00-12:20 Acceptability of human papillomavirus vaccine: A survey among master of business administration students in KwaZulu-Natal, South Africa
M E Hoque, University of KwaZulu-Natal, South Africa

Panel Discussion 12:20-12:30

AIDS/HIV vaccine

12:30-12:50 Antigenicity, structure and immunogenicity of the HIV-1 trimeric envelope glycoprotein spike
Richard T Wyatt, The Scripps Research Institute La Jolla, USA

Lunch Break 12:50-13:35 @ Multi Purpose Hall 2
Application of neutralization fingerprints in delineating antibody recognition in HIV-1 sera and antibody epitope prediction
Gwo-Yu Chuang, National Institutes of Health, USA
The balance of cellular and humoral immunity determines the level of protection offered by an HIV vaccine in macaque models of HIV infection
Timothy Fouts, Profectus BioSciences, Inc., USA
VAC-3S vaccine, a novel approach to the therapeutic management of HIV Infection. Overview of phase I and phase II clinical vaccine development programs
Raphael Ho Tsong Fang, InnaVirVax, France
Characterization of a potent and broad neutralizing antibody that specifically recognizes a point-substitution in the 35 motif of the HIV-1 gp41 protein
Patrice DEBRE, INSERM, France
Glycosylation of envelope gp120 is affected by producer cell type and impacts HIV-1 recognition by virus-specific antibodies and cell infection
Milan Raska, Palacky University, Czech Republic
Coffee Break 15:15-15:30 @ Auditorium 3 Foyer
DNA vaccination against drug resistance in chronic viral infections, example of HIV-1
Maria ISAGULIANTS, Karolinska Institutet, Sweden; Riga Stradins Univerisity, Latvia
Evaluation of immune response in small animal models by in vivo imaging
Stefan Petkov, Karolinska Institutet, Sweden
Human clinical trial of SAV001 prophylactic HIV vaccine and a new strategy for the development of therapeutic HIV vaccine
Chil-Yong Kang, The University of Western Ontario, Canada
Panel Discussion 16:30-16:40
Vaccine antigen modeling
Optimizing the delivery of novel immune potentiators within vaccine drug products
Manmohan Singh, Novartis Vaccines, USA
Natural killer cell subsets display helper and suppressor effects in modulating host viral responses in vivo
William J Murphy, UC Davis School of Medicine, USA
Strategies of antigen retargeting for improvement of DNA vaccine performance
Elizaveta Starodubova, Karolinska Institutet, Sweden
Cellular vaccines in Listeriosis: Role of the listeria antigen GAPDH
Carmen Alvarez-Dominguez, Instituto de Formacion e Investigacion Marques de Valdecilla, Spain
Regulation of STING expression via the RIG-I dependent RNA sensing pathway
Rongtuan Lin, McGill University, Canada
Cell engineering and antibiotic-free selection for vaccinal antigens production in E. coli: The ultimate sophistication to combine safety and productivity
Regis Sodoyer, Sanofi Pasteur, France
Leishmania recombinant antigen modulates the macrophage effector functions synergizing anti-leishmanial effects of miltefosine to facilitate early clearance of intracellular parasites
Sunil K Arora, PGIMER, India
Day 3 September 26, 2014
Auditorium 3A
Immuno-informatics in vaccine design
Session Chair: Malcolm E Thomas, Arbovax., Inc., USA
Immunization and human rights
Obradovic Zaremo, University of Sarajevo, Bosnia and Herzegovina
SlgN's clinical immunomonitoring platform for the assessment of immune responses in cohort studies and clinical trials
Brian Abel, Singapore Immunology Network, Singapore
Potent cellular and humoral immunogenicity of a pre-erythrocytic viral vectored malaria vaccine in African infants and children
Katie Ewer, University of Oxford, UK
The common computer-based influenza vaccination/epidemics surveillance system: Challenges and opportunities for primary health care in EU countries
Ljiljana Majnaric Trtica, JJ Strossmayer University, Croatia
The development of tuberculosis subunit vaccine EAMMH and regulation of vaccine induced immune memory by Rapamycin
Bingdong Zhu, Lanzhou University, China
Immunization programme in Indonesia: Overview- (Focusing on Streptococcus Pneumonia whole-cell vaccine)
Julitasari Sundoro, Indonesian Technical Advisory Group on Immunization, Indonesia
Panel Discussion 11:00-11:10
Vaccine formulation issues
Unique nanofabrication of antigens and adjuvants that effectively induces protective antibody and T cell responses
Frank J Malinoski, Liquidia Technologies Inc., USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution/University, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45-12:05</td>
<td>Development of a carbohydrate-based vaccine against meningococcal serogroup X infection</td>
<td>Francesco Berti, Novartis Vaccines, Italy</td>
<td></td>
</tr>
<tr>
<td>12:05-12:25</td>
<td>Effect of the inclusion of “contemporary” B. pertussis strains in the vaccine composition on temporal trends in B. pertussis population</td>
<td>Tatjana Pijese, Institute of Viralogy, Vaccines and Sera Torlak, Serbia</td>
<td></td>
</tr>
<tr>
<td>12:25-12:45</td>
<td>Specificities of health economics in the area of vaccines evaluation</td>
<td>Maarten J Postma, University of Groningen, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>12:45-13:05</td>
<td>The effect of new leishmania vaccine against Th1, Th2 as well as increasing of spleen white pulp size in Bulb/c mice after repeated exposure</td>
<td>Latifynia Afshinneh, Tehran University of Medical Sciences, Iran</td>
<td></td>
</tr>
<tr>
<td>13:05-13:15</td>
<td>Panel Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:15-14:00</td>
<td>Lunch Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00-14:20</td>
<td>A novel approach to the development of arboviral vaccines for dengue and chikungunya virus</td>
<td>Malcolm E Thomas, Arbovax, Inc., USA</td>
<td></td>
</tr>
<tr>
<td>14:20-14:40</td>
<td>Strategies toward developing a universal ExPEC vaccine capable of broad protection</td>
<td>Melha Mellata, Arizona State University, USA</td>
<td></td>
</tr>
<tr>
<td>14:40-15:00</td>
<td>The vaxonella platform for oral recombinant vaccine delivery</td>
<td>Rocky M Cranenburgh, Prokarium Ltd., UK</td>
<td></td>
</tr>
<tr>
<td>15:00-15:20</td>
<td>Oral vaccine platform elicits neutralizing antibody responses to influenza</td>
<td>Sean Tucker, Vaxart, Inc., USA</td>
<td></td>
</tr>
<tr>
<td>15:20-15:40</td>
<td>A rationally designed form of the TLR5 agonist, flagellin, supports superior immunogenicity of influenza B globular head vaccines</td>
<td>Langzhou Song, VaxInnate Corporation, USA</td>
<td></td>
</tr>
<tr>
<td>15:55-16:15</td>
<td>Responsibility: A “first person ethics” for vaccination</td>
<td>Fermin J Gonzalez-Melado, Pontifical Institute “John Paul II” for Studies on Marriage and Family, Spain</td>
<td></td>
</tr>
<tr>
<td>16:15-16:35</td>
<td>Development of a truly improved whooping cough vaccine</td>
<td>Marcel Tholen, Illiad Biotechnologies, Scotland</td>
<td></td>
</tr>
<tr>
<td>16:35-16:55</td>
<td>Translational development and preclinical efficacy of a multi-antigen T cell epitope-enriched DNA vaccine against Leishmaniasis</td>
<td>Christiane Juhls, MOLOGEN AG, Germany</td>
<td></td>
</tr>
<tr>
<td>16:55-17:15</td>
<td>Oral infections in Guinea Conakry</td>
<td>Sylvain Haba, Centre Des Soins Medico-Tradi-Spirituels Talithakoumi, Guinea Conakry</td>
<td></td>
</tr>
<tr>
<td>17:15-17:25</td>
<td>Panel Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30-14:30</td>
<td>Poster Presentations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30-14:30</td>
<td>VAC-001 Using NYVAC vectors as vaccine candidates for Leishmaniasis</td>
<td>Ernesto Mejias Perez, Centro Nacional de Biotecnologia, Spain</td>
<td></td>
</tr>
<tr>
<td>12:30-14:30</td>
<td>VAC-002 Enhancement of antigen-specific CD4 T cell response through spacer modification in vaccinia virus promoters</td>
<td>Mauro Di Pilato, Centro Nacional de Biotecnologia, Spain</td>
<td></td>
</tr>
<tr>
<td>12:30-14:30</td>
<td>VAC-003 IL-34 suppresses Candida albicans induced TNF-a production by M1 macrophages through down-regulation of Dectin-1 and TLR2 expression</td>
<td>Rong Xu, Cardiff University, UK</td>
<td></td>
</tr>
<tr>
<td>12:30-14:30</td>
<td>VAC-004 Protection of chickens against Chlamydia psittaci challenge by mucosal immunization with the major outer membrane protein</td>
<td>Daisy Vanrompay, Ghent University, Belgium</td>
<td></td>
</tr>
<tr>
<td>12:30-14:30</td>
<td>VAC-005 The single intradermal cervical comparative testand Johne’s disease ELISA diagnostics</td>
<td>Aileen Kennedy, Animal &amp; Grassland Research and Innovation Centre, Ireland</td>
<td></td>
</tr>
<tr>
<td>12:30-14:30</td>
<td>VAC-006 Antigen on nanoparticles enhances anti-tumor immune responses as well as animal antibody responses in vivo</td>
<td>Junichiro Mizuguchi, Tokyo Medical University, Japan</td>
<td></td>
</tr>
<tr>
<td>12:30-14:30</td>
<td>VAC-007 Hepatitis B immunizationstatus of a miscellaneous population of workers</td>
<td>Frederic DESCHAMPS, University Hospital of Reims, France</td>
<td></td>
</tr>
<tr>
<td>12:30-14:30</td>
<td>VAC-008 Retinoic acid promotes long lasting mucosal and systemic immune responses after mucosal priming and systemic boosting in mice</td>
<td>Silvia Vendetti, Istituto Superiore di Sanita, Italy</td>
<td></td>
</tr>
<tr>
<td>12:30-14:30</td>
<td>VAC-009 Experimental chagas disease: Vaccination with Trypanosoma rangeli modulate the innate immune response in mice challenged with Trypanosoma cruzi</td>
<td>Beatriz Basso, National University of Cordoba, Argentina</td>
<td></td>
</tr>
<tr>
<td>12:30-14:30</td>
<td>VAC-010 Effect of preventive and therapeutic vaccination schedules with Trypanosoma rangeli against Trypanosoma cruzi infection in a mouse model of Chagas’ disease</td>
<td>Beatriz Basso, National University of Cordoba, Argentina</td>
<td></td>
</tr>
<tr>
<td>12:30-14:30</td>
<td>VAC-011 Generation of genetically inactivated Salmonella Gallinarum ghost and evaluation of its potential as an effective inactivated vaccine candidate against fowl typhoid</td>
<td>Chetan V Jawale, Chonbuk National University, Korea</td>
<td></td>
</tr>
</tbody>
</table>
**VAC-012**

Construction of tightly regulated E-lysis cassette for production of genetically inactivated Salmonella Enteritidis ghost

Chetan V. Jawale, Chonbuk National University, Korea

**VAC-013**

Increasing of alive plague vaccine efficiency

Ponomaryova Tatyana, Kazakh Scientific Center of Quarantine and Zoonotic Diseases, Kazakhstan

**VAC-014**

Vaccine in elderly patients with diabetes

Atsuko Hata, The Tazuke Kofukai Medical Research Institute, Japan

**VAC-015**

Analysis of phage displayed antibody fragment - pros and cons of Phage ELISA and RISE methods

Barbara Kalenik, Institute of Biochemistry and Biophysics Polish Academy of Sciences, Poland

**VAC-016**

HIV-1 Nef protein carries multiple epitopes suitable for induction of cellular immunity for an HIV vaccine in Africa

Athina KILPELAINEN, Karolinska Institutet, Sweden

**VAC-017**

Retargeting of HIV reverse transcriptase to MHC class II processing improves its immunogenicity

Anastasia Latanova, Karolinska Institutet, Sweden

**VAC-018**

Lipopolysaccharide of Coxiella burnetii. A promising candidate molecule in a search for a new Q fever vaccine

Rudolf Toman, Slovak Academy of Sciences, Slovak Republic

**VAC-019**

Long-term immune response to Hepatitis B Virus (HBV) vaccine among type 1 diabetic students: Do they need a booster?

Engy M. El-Ghitany, Alexandria University, Egypt

**VAC-020**

Bivalent candidate vaccine against HCV and HIV-1: Construction and biological evaluation

Mohammad Reza Aghasadeghi, Pasteur Institute of Iran, Iran

**VAC-021**

An early report on a local project about primary health care to improve the communication and the compliance in the elderly for vaccinal campaigns against influenza

Filippo de Nicolellis, Primary Health Care, Italy

**VAC-022**

Cyclic GMP-AMP has mucosal adjuvant activity in mice

Christina Rueckert, Helmholtz Center for Infection Research, Germany

**VAC-023**

Local and systemic antibody and cell-mediated immune response after vaccination and infection with porcine respiratory and reproduction system (PRRS) virus

Miroslav Toman, Veterinary Research Institute, Czech Republic

**VAC-024**

Using monoclonal antibodies to understand the molecular basis for the cross bactericidal activity of NHBA antigen

Claudia Facciotti, Novartis, Italy

**VAC-025**

Expression profile of cytokine transcripts and Cell mediated immune response in peripheral blood mononuclear cells of sheep following vaccination of pentavalent bluetongue vaccine

Molalegne Bitew, Jimma University, Ethiopia

**VAC-026**

In vitro molecular analysis of ribosomal initiation complexes assembly and RNA-protein interactions during the initiation of translation of a prototype Coxsackievirus B3 and a live-attenuated Sabin 3-like RNAs

Amira SOUII, Universite de Tunis El Manar, Tunisia

---

**Contact Details**

OMICS Group Inc.
2360 Corporate Circle, Suite 400
Henderson, NV 89074-7722, USA
Ph: +1-888-843-8169
Fax: +1-650-618-1417
contact@omicsgroup.com

OMICS Publishing Group
5716 Corsa Ave., Suite 110, Westlake
Los Angeles, CA 91362-7354, USA
Ph: +1-650-268-9744
Fax: +1-650-618-1414
contact.americas@omicsonline.org

OMICS Group
SEZ Unit, Building No. 20, 9th Floor
APIIC Layout, HITEC City
Hyderabad-50081, Telangana, INDIA
Ph: 040-40131823, 040-47482222
contact.asiapacific@omicsonline.org

Toll free
USA & Canada: +1-800-216-6499
Australia: +1-800-651-097
Europe: 0805-080048
Bookmark your dates

Asia Pacific Global Summit and Expo on Vaccines & Vaccination
June 01-03, 2015  Brisbane, Australia

Euro Global Summit and Expo on Vaccines & Vaccination
August 17-19, 2015  Birmingham, UK

Indo Global Summit and Expo on Vaccines & Vaccination
September 28-30, 2015  New Delhi, India

Dubai Global Summit and Expo on Vaccines & Vaccination
September 28-30, 2015  Dubai, UAE

American Global Summit and Expo on Vaccines & Vaccination
October 05-07, 2015  San Francisco, USA